Search research articles
Contact Us
Filters
Showing results (31-40 of 78) with videos related to
Page
of 8
Sort By:
Molecular Imaging and Biology
|
May 6, 2016
[<sup>89</sup>Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer
Richard Laforest, Suzanne E Lapi, Reiko Oyama, et al.
Molecular & Cellular Proteomics : MCP
|
April 14, 2012
Identification of targets of c-Src tyrosine kinase by chemical complementation and phosphoproteomics
Isabel Martinez Ferrando, Raghothama Chaerkady, Jun Zhong, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
February 22, 2019
Retrospective Analysis of Treatment Patterns and Effectiveness of Palbociclib and Subsequent Regimens in Metastatic Breast Cancer
Jing Xi, Aabha Oza, Shana Thomas, et al.
Cancer Discovery
|
August 6, 2015
HER2 activating mutations are targets for colorectal cancer treatment
Shyam M Kavuri, Naveen Jain, Francesco Galimi, et al.
Breast Cancer Research and Treatment
|
February 15, 2018
Evaluation of [<sup>89</sup>Zr]trastuzumab-PET/CT in differentiating HER2-positive from HER2-negative breast cancer
Farrokh Dehdashti, Ningying Wu, Ron Bose, et al.
Cancer Research
|
June 5, 2023
Breast Cancer Mutations HER2V777L and PIK3CAH1047R Activate the p21-CDK4/6-Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
Xiaoqing Cheng, Yirui Sun, Maureen Highkin, et al.
JCO Precision Oncology
|
February 17, 2022
Response of a Metastatic Breast Carcinoma With a Previously Uncharacterized ERBB2 G776V Mutation to Human Epidermal Growth Factor Receptor 2-Targeted Therapy
Yakov Chudnovsky, Runjun D Kumar, Alexa B Schrock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 21, 2025
Detection of Circulating Tumor DNA Using a Tissue-Free Epigenomic Assay Is a Highly Prognostic Biomarker in Early-Stage Triple-Negative Breast Cancer
Foluso O Ademuyiwa, Cynthia X Ma, Katherine Weilbaecher, et al.
Biorxiv : the Preprint Server for Biology
|
July 17, 2025
HER2; p53 Co-mutated Cancers Show Increased Histone Acetylation and are Sensitive to Neratinib plus Trastuzumab Deruxtecan
Xiaoqing Cheng, Jacob Hsia, Jesus Iraheta, et al.
Cancer Discovery
|
December 11, 2012
Activating HER2 mutations in HER2 gene amplification negative breast cancer
Ron Bose, Shyam M Kavuri, Adam C Searleman, et al.
Page
of 8
Search research articles
Search
Showing results (31-40 of 78) with videos related to
Sort By:
Page
of 8
Molecular Imaging and Biology
|
May 6, 2016
[<sup>89</sup>Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer
Richard Laforest, Suzanne E Lapi, Reiko Oyama, et al.
Molecular & Cellular Proteomics : MCP
|
April 14, 2012
Identification of targets of c-Src tyrosine kinase by chemical complementation and phosphoproteomics
Isabel Martinez Ferrando, Raghothama Chaerkady, Jun Zhong, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
February 22, 2019
Retrospective Analysis of Treatment Patterns and Effectiveness of Palbociclib and Subsequent Regimens in Metastatic Breast Cancer
Jing Xi, Aabha Oza, Shana Thomas, et al.
Cancer Discovery
|
August 6, 2015
HER2 activating mutations are targets for colorectal cancer treatment
Shyam M Kavuri, Naveen Jain, Francesco Galimi, et al.
Breast Cancer Research and Treatment
|
February 15, 2018
Evaluation of [<sup>89</sup>Zr]trastuzumab-PET/CT in differentiating HER2-positive from HER2-negative breast cancer
Farrokh Dehdashti, Ningying Wu, Ron Bose, et al.
Cancer Research
|
June 5, 2023
Breast Cancer Mutations HER2V777L and PIK3CAH1047R Activate the p21-CDK4/6-Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
Xiaoqing Cheng, Yirui Sun, Maureen Highkin, et al.
JCO Precision Oncology
|
February 17, 2022
Response of a Metastatic Breast Carcinoma With a Previously Uncharacterized ERBB2 G776V Mutation to Human Epidermal Growth Factor Receptor 2-Targeted Therapy
Yakov Chudnovsky, Runjun D Kumar, Alexa B Schrock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 21, 2025
Detection of Circulating Tumor DNA Using a Tissue-Free Epigenomic Assay Is a Highly Prognostic Biomarker in Early-Stage Triple-Negative Breast Cancer
Foluso O Ademuyiwa, Cynthia X Ma, Katherine Weilbaecher, et al.
Biorxiv : the Preprint Server for Biology
|
July 17, 2025
HER2; p53 Co-mutated Cancers Show Increased Histone Acetylation and are Sensitive to Neratinib plus Trastuzumab Deruxtecan
Xiaoqing Cheng, Jacob Hsia, Jesus Iraheta, et al.
Cancer Discovery
|
December 11, 2012
Activating HER2 mutations in HER2 gene amplification negative breast cancer
Ron Bose, Shyam M Kavuri, Adam C Searleman, et al.
Page
of 8